Skip to main content

Valeria Tubita

Institutions of which they are part

Main researcher
Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

Valeria Tubita

Institutions of which they are part

Main researcher
Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

Projects

Estudio preclínico de la combinación de terapias anti-HER2 e inhibidores de PARP en el cáncer de endometrio HER2 positivo con Deficiencia de Recombinación Homóloga (HRD).

IP: Valeria Tubita
Collaborators: Francesc Xavier Serra Marin, Eva Colas Ortega, Antonio Gil Moreno, Marta Rebull Santamaria, Lourdes Elena Salazar Huayna
Funding agency: Asociación Española Contra el Cáncer
Funding: 8539.84
Reference: SNRGS259715TUBI
Duration: 01/12/2025 - 30/11/2027

Búsqueda de firmas proteómicas y dianas terapéuticas en el cáncer de ovario seroso de alto grado avanzado resistente a platino

IP: Antonio Gil Moreno
Collaborators: Vicente Bebia Conesa, Francesc Xavier Serra Marin, Marta Rebull Santamaria, Martina Angeles Fite, Melissa Bradbury Lobato, Lourdes Elena Salazar Huayna, Melek Denizli , Valeria Tubita
Funding agency: Instituto de Salud Carlos III
Funding: 196250
Reference: PI24/01509
Duration: 01/01/2025 - 31/12/2027

Terapia Combinada de SYD985 y Niraparib: Un Nuevo Horizonte en el Tratamiento Personalizado del Cáncer de Endometrio HER2/neu Positivo

IP: Valeria Tubita
Collaborators: -
Funding agency: Fundació Santiago Dexeus Font
Funding: 6000
Reference: DEXEUS/PROJECTE/TUBITA/2024
Duration: 30/12/2024 - 30/12/2026

Cytomark - Desarrollo de un test diagnóstico personalizado y no invasivo de cáncer de endometrio en el fluido cervical

IP: Eva Colas Ortega
Collaborators: Vicente Bebia Conesa, Angel García Jiménez, Carina Masferrer Ferragutcasas, Silvia Cabrera Diaz, Antonio Gil Moreno, Marta Rebull Santamaria, Ana Luzarraga Aznar, Irene De la Calle Fuentes, Raquel Delgado Gil, Melek Denizli , Valeria Tubita
Funding agency: Asociación Española Contra el Cáncer
Funding: 188000
Reference: PERME212443COLA
Duration: 01/01/2022 - 31/01/2026

Related news

The Biomedical Research in Gynaecology group at VHIR has contributed to this international resource with endometrial cancer organoid models.

The ten groups within the Cancer Area combine basic, translational and clinical research to identify new targets, biomarkers and therapeutic strategies

The study evaluated the results of combining SYD985, a HER2 antibody conjugated to a potent cytotoxic drug, and niraparib, an inhibitor of DNA damage repair.

Related professionals

Franco Marinello

Franco Marinello

Main researcher
General Surgery
Read more
Paula Fernández Álvarez

Paula Fernández Álvarez

Research technician
Genetics Medicine
Read more
Maider Arando Lasagabaster

Maider Arando Lasagabaster

Predoctoral researcher
Infectious Diseases
Read more
Fernando Clau Terré

Fernando Clau Terré

Senior researcher
Shock, Organ Dysfunction and Resuscitation
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.